FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:1313-1314 April 30, 1998 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Delmas, P. D. PubMed Citation

To the Editor: The article by Delmas et al. (Dec. 4 issue)¹ suggests that raloxifene has many of the beneficial effects of estrogen in postmenopausal women, but it contained little information on adverse events. At a public Food and Drug Administration hearing in November 1997, the manufacturer reported that raloxifene (60 mg per day) significantly increased hot flashes, leg pain, and thromboembolic events, as compared with placebo. In view of this information, an accounting of these adverse events in the trial is warranted. Furthermore, we are not told how many women were in each group at 6, 12, and 24 . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Johnston, C. C. Jr, Bjarnason, N. H., Cohen, F. J., Shah, A., Lindsay, R., Mitlak, B. H., Huster, W., Draper, M. W., Harper, K. D., Heath III, H., Gennari, C., Christiansen, C., Arnaud, C. D., Delmas, P. D. (2000). Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women: Three-Year Data From 2 Double-blind, Randomized, Placebo-Controlled Trials. Arch Intern Med 160: 3444-3450 [Abstract] [Full Text]  
• Cosman, F., Lindsay, R. (1999). Selective Estrogen Receptor Modulators: Clinical Spectrum. Endocr. Rev. 20: 418-434 [Abstract] [Full Text]  
• Khovidhunkit, W., Shoback, D. M. (1999). Clinical Effects of Raloxifene Hydrochloride in Women. ANN INTERN MED 130: 431-439 [Abstract] [Full Text]